Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

Item

http://www.wikidata.org/entity/Q36767782

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@ast

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@en

type

Item

label

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@ast

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@en

prefLabel

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@ast

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@en

P1476

Effectiveness of golimumab in clinical management of patients with rheumatoid arthritis

@en

P2093

Eisuke Shono

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Biologic agents in rheumatoid arthritis: an update for managed care professionals

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study.

The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy.

Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.

Studies of the efficacy and safety of methotrexate at dosages over 8 mg/week using the IORRA cohort database.

P304

95-100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40268-013-0010-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236104464

http://www.w3.org/2001/XMLSchema#string

P698

23553540

http://www.w3.org/2001/XMLSchema#string

P932

3627033

http://www.w3.org/2001/XMLSchema#string